Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon's PLX3397, a novel oral agent, was found to selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients in preclinical studies.
Subscribe to our email newsletter
PLX3397 is an oral agent that selectively co-inhibits three key targets, allows down-modulation of a number of cell types, as well as inhibits Flt3 mutations that are responsible for AML.
In a preclinical model of AML, PLX3397 showed tumor regression and retained activity against certain drug-resistant forms of mutated Flt3 that can occur with other treatments.
Phase 1 dose escalation testing in patients with solid tumors showed that PLX3397 reached therapeutic drug levels that were well tolerated at the doses tested, and further the two ongoing Phase 2 studies will evaluate PLX3397.
In addition, PLX3397 has also been tested in primary AML patient blood samples, which showed a clear dose response to drug at clinically achievable drug levels.